Skip to main content
. Author manuscript; available in PMC: 2012 Apr 25.
Published in final edited form as: Inflamm Bowel Dis. 2008 Nov;14(11):1528–1541. doi: 10.1002/ibd.20512

TABLE 6B.

Multidimensionality Reduction (MDR) (IL23R as Dominant, IBDs and ATG16 as Genotypic, NOD2 Considered as Addictive)

No. of Markers Combinations Best Model Cross-Validation Consistency Prediction Error Significance, P-value (Based on 1000 Permutations)
1 NOD2a 9 0.40 0.019
2 NOD2, IBD5_OCTN2b 6 0.37 0.001
3 NOD2, IBD5_OCTN1, ATG16L1c 4 0.38 0.003
4 NOD2, IBD5_OCTN1, ATG16L1, IL23R_rs10889677d 5 0.39 0.006
a

NOD2 in jointly additive mode (o variant, 1 variant, 2 variants).

b

IBD5_OCTN2 (rs2631367) in genotypic mode (AA, GA, GG); NOD2 in jointly additive mode (o variant, 1 variant, 2 variants).

c

IBD5_OCTN1 (rs1050152) in genotypic mode (TT, CT, CC); ATG16L1 (rs2241880) in genotypic mode (GG, AG, AA); NOD2 in jointly additive mode (0 variant, 1 variant, 2 variants).

d

IBD5_OCTN1 (rs1050152) in genotypic mode (TT, CT, CC); ATG16L1 (rs2241880) in genotypic mode (GG, AG, AA); NOD2 in jointly additive mode (0 variant, 1 variant, 2 variants); IL23R_rs10889677 in dominant mode (AA/AC vs. CC).